Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 51 (3), 119-125

Clinical Implications of the Hippo-YAP Pathway in Multiple Cancer Contexts


Clinical Implications of the Hippo-YAP Pathway in Multiple Cancer Contexts

Han-Byul Kim et al. BMB Rep.


The Hippo pathway plays prominent and widespread roles in various forms of human carcinogenesis. Specifically, the Yes-associated protein (YAP), a downstream effector of the Hippo pathway, can lead to excessive cell proliferation and the inhibition of apoptosis, resulting in tumorigenesis. It was reported that the YAP is strongly elevated in multiple types of human malignancies such as breast, lung, small intestine, colon, and liver cancers. Recent work indicates that, surprisingly, Hippo signaling components' (SAV1, MST1/2, Lats1/2) mutations are virtually absent in human cancer, rendering this signaling an unlikely candidate to explain the vigorous activation of the YAP in most, if not all human tumors and an activated YAP promotes the resistance to RAF-, MAPK/ERK Kinase (MEK)-, and Epidermal growth factor receptor (EGFR)-targeted inhibitor therapy. The analysis of YAP expressions can facilitate the identification of patients who respond better to an anti-cancer drug treatment comprising RAF-, MEK-, and EGFR-targeted inhibitors. The prominence of YAP for those aspects of cancer biology denotes that these factors are ideal targets for the development of anti-cancer medications. Therefore, our report strongly indicates that the YAP is of potential prognostic utility and druggability in various human cancers. [BMB Reports 2018; 51(3): 119-125].

Conflict of interest statement


The authors have no conflicting interests.


Fig. 1
Fig. 1
Models of the Hippo pathway in mammals. The Hippo pathway regulation is shown here: When the YAP is relieved from inhibition through phosphorylation-dependent or -independent mechanisms in mammals, its nuclear translocation leads the target gene expression into the regulation of cellular proliferation, apoptosis, and differentiation.

Similar articles

See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles


    1. Harvey K, Tapon N. The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 2007;7:182–191. doi: 10.1038/nrc2070. - DOI - PubMed
    1. Meignin C, Alvarez-Garcia I, Davis I, Palacios IM. The salvador-warts-hippo pathway is required for epithelial proliferation and axis specification in Drosophila. Curr Biol. 2007;17:1871–1878. doi: 10.1016/j.cub.2007.09.062. - DOI - PMC - PubMed
    1. Zhang X, Milton CC, Humbert PO, Harvey KF. Transcriptional output of the Salvador/warts/hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines. Cancer Res. 2009;69:6033–6041. doi: 10.1158/0008-5472.CAN-08-4592. - DOI - PubMed
    1. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122:421–434. doi: 10.1016/j.cell.2005.06.007. - DOI - PubMed
    1. Kango-Singh M, Singh A. Singh, Regulation of organ size: insights from the Drosophila Hippo signaling pathway. Dev Dyn. 2009;238:1627–1637. doi: 10.1002/dvdy.21996. - DOI - PubMed

MeSH terms